Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia

Daewoong Pharmaceutical

Status and phase: Completed; Phase 2

Conditions: Postherpetic Neuralgia

Treatments: Drug: DWP05195; Drug: Control

Study type: Interventional

Funder types: Industry

Identifiers

NCT01557010

DWP05195-P003

Details and patient eligibility

About

The purpose of this study is to evaluate efficacy, safety of administered DWP05195 in Postherpetic Neuralgia.

Enrollment: 140 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or Female subjects aged 20 to 80 years
• Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN).
• Subjects must have pain present for > 3 months after healing of the acute herpes zoster skin rash.

Exclusion criteria

• Other severe pain that may potentially confound pain assessment.
• Subjects with symptoms of neuropathic pain applied Medical Equipment
• Within 2 years: Subjects were diagnosed with cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

140 participants in 4 patient groups, including a placebo group

Treatment A

Experimental group

Treatment:

Drug: DWP05195

Drug: DWP05195

Drug: DWP05195

Treatment B

Experimental group

Treatment:

Drug: DWP05195

Drug: DWP05195

Drug: DWP05195

Treatment C

Experimental group

Treatment:

Drug: DWP05195

Drug: DWP05195

Drug: DWP05195

Treatment D

Placebo Comparator group

Treatment:

Drug: Control